key: cord-0948260-m2fwc0f2
authors: Eder, Lihi; Croxford, Ruth; Drucker, Aaron M.; Mendel, Arielle; Kuriya, Bindee; Touma, Zahi; Johnson, Sindhu R.; Cook, Richard; Bernatsky, Sasha; Haroon, Nigil; Widdifield, Jessica
title: Understanding COVID‐19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Population‐based analysis of SARS‐CoV‐2 Testing
date: 2021-09-06
journal: Arthritis Care Res (Hoboken)
DOI: 10.1002/acr.24781
sha: e97390b7f4a1cb4076b69c03563a9e29163e3c46
doc_id: 948260
cord_uid: m2fwc0f2

OBJECTIVE: To investigate the incidence of and factors associated with SARS‐CoV‐2 testing and infection in immune mediated inflammatory diseases (IMIDs) versus matched non‐IMIDs comparators from the general population. METHODS: We conducted a population‐based, matched cohort study among adult residents from Ontario, Canada, from January to December 2020. We created cohorts for the following IMIDs: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases, multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica and vasculitis. Each patient was matched with five patients without IMIDs based on socio‐demographic factors. We estimated the incidence of SARS‐CoV‐2 testing and infection in IMIDs and non‐IMIDs patients. Multivariable logistic regressions assessed odds of SARS‐CoV‐2 infection. RESULTS: We studied 493,499 patients with IMIDs and 2,466,946 patients without IMIDs. Patients with IMIDs were more likely to have at least one SARS‐CoV‐2 test, versus patients without IMIDs (27.4% vs. 22.7%), but the proportion testing positive for SARS‐CoV‐2 was identical (0.9% in both groups). Overall, IMIDs patients had 20% higher odds of being tested for SARS‐CoV‐2 (odds ratio (OR) 1.20, 95% CI 1.19, 1.21). The odds of SARS‐CoV‐2 infection varied across IMIDs groups but was not significantly elevated for most IMID groups compared with non‐IMIDs. The odds of SARS‐CoV‐2 infection was lower in IBD and MS and marginally higher in RA and iritis. CONCLUSIONS: Patients across all IMIDs were more likely to be tested for SARS‐CoV‐2 versus those without IMIDs. The risk of SARS‐CoV‐2 infection varied across disease sub‐groups.

This article is protected by copyright. All rights reserved Immune mediated inflammatory diseases (IMIDs) are complex disorders caused by a combination of genetic susceptibility and environmental factors [1] . Population-based studies have shown that over 5% of the general population have a diagnosis of at least one IMID [2, 3] . Patients with IMIDs have unique characteristics that raise concerns regarding their risk of acquiring SARS-CoV-2 and outcomes associated with the virus. A higher risk of infections, including viral illnesses, has been reported in a variety of IMIDs [4] [5] [6] . Both abnormalities in the host immune defense intrinsic to the underlying IMIDs, and due to immune modulating treatments, contribute to this risk [7, 8] . In addition, a biologically susceptible host may have heightened risk depending on sociodemographic factors including individual and societal behaviours and community spread.

The detection of COVID-19 infection and thus the reported disease incidence rates are directly influenced by SARS-CoV-2 testing. SARS-CoV-2 testing is an important public health measure to monitor and control viral spread in the general population [9] . Approaches to SARS-CoV-2 testing have evolved over time and were a limited resource in early phases of the pandemic. Local recommendations and access to testing also varied across jurisdictions and populations. SARS-CoV-2 testing rates are influenced by demographics (sex, race/ethnicity), socioeconomic factors and comorbidities [10, 11] .

Despite multiple studies on the risk of COVID-19 infection and its complications in IMIDs, evidence from population-based studies is limited [12] . Observational studies reliant on self-report of infection status, hospital admissions, and targeted testing in selected populations have been reported but are prone to selection biases [13] . Reported COVID-19 infection rates are functions of sociodemographic factors and comorbidities which influence the propensity of individuals to undergo SARS-CoV2 testing [11, 14] . Previous studies that have restricted their analysis to hospitalized patients, people tested for active infection, or people who volunteered to participate are most susceptible to collider bias as the relationships between any variables that relate to outcome will be distorted compared to among the general population [13] . Since it is challenging to identify all such potential confounders to mitigate this collider bias, accurate estimates of COVID-19 risk in IMIDs are best obtained from studies involving unselected population-based data and careful adjustment of factors affecting SARS-Cov-2 testing.

This article is protected by copyright. All rights reserved Our study aims to fill this knowledge gap by investigating the incidence and factors associated with SARS-CoV-2 testing and positivity ('SARS-CoV-2 infection') in IMIDs versus matched non-IMIDs patients using population health administrative data from Ontario, Canada.

We conducted a population-based, matched cohort study (involving patients with IMIDs matched with non-IMIDs comparators) using Ontario health administrative data, to assess for SARS-CoV-2 testing and infection between January 1, 2020 to December 17, 2020. The first patient with COVID-19 in Ontario was reported in January 23, 2020. Ontario comprises almost 40% of the Canadian population with 14.7 million individuals in 2020. Our study included adults ages 20 and older living in the province. The Ontario Health Insurance Plan (OHIP) is a public, single-payer system that covers hospital admissions, physician services and tests for SARS-CoV-2 for all Ontario residents [15] .

Health care encounters are recorded in administrative health databases, which are linked using an encoded identifier that is unique to each resident, provider, and facility. The data used in the study are held securely and analyzed in linked, encoded form at ICES (www.ices.on.ca). The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board.

We used physician service claims and provincial hospitalization databases to assemble 10 cohorts of patients with the following IMIDs: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), 

This article is protected by copyright. All rights reserved We used the OHIP physician service claims database to identify diagnosis codes of IMIDs and information about pre-existing comorbidities. These diagnoses are coded using a modification of the International Classification of Diseases Version 8 (ICD-8) [16] . We obtained information on physician specialty by linking to the ICES Physician Database. Hospital diagnoses for IMID were also identified using the Canadian Institute for Health Information's Discharge Abstract Database using ICD-10. When available, we used validated IMIDs case definitions [17] [18] [19] [20] [21] , most requiring multiple OHIP diagnosis codes, with at least one rendered by a relevant specialist, or a hospital discharge diagnosis. For the remaining IMIDs, we used a similar approach that was based on a combination of physician visits for the specific IMID, including at least one by a relevant specialist, or at least one hospital discharge diagnosis. Case definitions for inclusion in each cohort are shown in the Supplement. Study entry required that a person was diagnosed with at least one of the above detailed IMIDs, be alive, older than 20 years of age and living in Ontario on January 1, 2020. To ensure accurate baseline information, patients were also required to be eligible for OHIP coverage for at least 3 years prior to the study start date.

Each patient was matched with 5 non-IMID comparators based on age (within 5 years), sex, region of residence (Local Health Integration Network, LHIN) at study entry (January 1, 2020), and residing in a long term care (LTC) facility (within 120 prior to study entry).

Information regarding patients 'demographic characteristics, vital status and health insurance status were obtained from the Registered Persons Database. Information about residential income quintile was identified using Statistics Canada's census data. LTC residence was ascertained using the Complex Continuing Care-LTC database, which records the mandatory assessments performed at admission and quarterly on all LTC residents. Co-morbidities were assessed within the 3 years prior to the study entry. The number of Johns Hopkins Aggregated Diagnosis Groups®, System Version 10 [27] was calculated. Patients were also classified based on their resident 'postal code to living in rural or urban area.

This article is protected by copyright. All rights reserved Information about SARS-CoV-2 testing and positive results on viral RNA PCR testing (SARS-CoV-2 infection) was available from the Ontario Laboratory Information System (OLIS). OLIS captures approximately 88% of all laboratory identified SARS-CoV-2 cases reported by the province during the study period [22, 23] . For each subject, we identified whether they had had at least one test between January 1, 2020 to December 17, 2020, along with the result of each test. During the study period, the testing criteria for SARS-CoV-2 in Ontario have changed. Due to limited capacity of SARS-CoV-2 testing in early stages of the pandemic, testing focused on people who presented with COVID-19 symptoms or signs who required admission to the hospital or those belonging to high risk groups including returning travelers, people who lived or worked in congregate living setting and institutions and those with occupational exposures (e.g. healthcare workers). A priority in testing was also given to symptomatic patients requiring frequent contact with the healthcare system due to their underlying medical conditions [24] . With increased testing capacity, the recommendations for testing were broadened and as of the end of May 2020 the Ontario Ministry of Health guidelines recommends performing SARS-CoV-2 testing in people presenting with at least one COVID-19 sign or symptom or in high-risk asymptomatic people, such as those who had contacts with confirmed COVID-19 cases or workers and residents of specific outbreak sites (e.g. long-term care (LTC) homes) [25] .

We calculated descriptive statistics for patient characteristics among those with and without IMIDs (at time study entry). We calculated standardized differences between the two groups with a standardized difference larger than 0.10 indicating a clinically meaningful difference [26] . Crude and age-sexstandardized cumulative incidence of SARS-CoV-2 testing and infection (along with 95% confidence intervals (CIs)) were reported for each IMID group and then over-all, using the 2016 Ontario population age structure for age and sex standardization. Patients were followed from study entry (January 2020) until the they experienced any of the following outcomes (whichever came first): end of study (December 17, 2020), death or first SARS-CoV-2 testing or infection (for the respective analysis).

We compared the cumulative incidence of those with at least one SARS-CoV-2 test, as well as those with SARS-CoV-2 infection between all study patients with and without IMIDs. We used multivariable logistic regression to compare SARS-CoV-2 testing and SARS-CoV-2 infection in

This article is protected by copyright. All rights reserved IMIDs versus non-IMIDs patients, adjusted for sociodemographic factors and comorbidities and accounting for matching. Each regression model included the specific IMID diagnosis and the following covariates: age, sex, LTC residence, comorbidities (number of Johns Hopkins Aggregated Diagnosis Groups ® , System Version 10 [27] , socioeconomic status (by census neighborhood income quintiles) and rurality (classified as urban and rural based on residents 'postal code). Then, to assess specific risk factors for SARS-CoV-2 testing and SARS-CoV-2 infection we restricted the analysis to patients with IMIDs alone. We assessed all above variables as potential risk factors for each of these two outcomes separately (adjusting for IMID type) and reported their estimated adjusted odds ratios (OR) along with 95% confidence intervals (CI). 

During the study period, a total of 134,981 (27.4%) patients with IMIDs were tested for SARS-CoV-2 compared with 693,796 (23.4%) of patients without IMIDs. No tests were performed in any of the study patients prior to March 2020, therefore, the results are reported as of as this month onward. The age-sex-standardized testing rate was higher among IMIDs patients compared to non-IMIDs starting in March 2020 and remained elevated throughout the study period ( Figure 1A) . The overall age-and sex-standardized cumulative incidence of SARS-CoV-2 testing was significantly higher among IMIDs than non-IMIDs (2,691. 8 

This article is protected by copyright. All rights reserved patients per 10,000 population, respectively). Testing rates were significantly higher across all IMID groups versus their respective matched non-IMID comparators, being highest in individuals with vasculitis (3,124.1 per 10,000 population), IBD (2,929.9 per 10,000 population) and SARDs (2,920.9 per 10,000 population) ( Figure 1B) . The regression analysis showed that IMID patients were more likely to undergo SARS-CoV-2 testing with a 29% higher odds of being tested (unadjusted OR 1.29 (95% CI 1.28, 1.29), Figure 2 ), and this association remained significant in the multivariable analysis (OR 1.20, 95% CI 1.19, 1.21). The association between having IMID and being tested for SARS-CoV-2 was found across all IMID subgroups and was highest in those with vasculitis (OR 1.42) and PMR (OR 1.40) (Figure 2 ).

Among patients with a diagnosis of IMID, the factor most strongly associated with SARS-CoV-2 testing was residing in a LTC facility (OR 16.63, Table 1 ). Other factors significantly associated with testing among IMID patients included female sex (OR 1.17), higher number of ADGs (OR for higher ADG categories compared to the lowest ADG category ranged from 1.45 to 2.60) and younger age (OR 0.92). 

This article is protected by copyright. All rights reserved found in IBD (OR 0.75 (95% CI 0.68, 0.84)), MS (OR 0.77 (95% CI 0.68, 0.87)) and psoriasis (OR 0.94 (95% CI 0.88, 0.99)). A significant, yet weaker association was found between iritis (OR 1.13 (95% CI 1.02, 1.26)) and RA (OR 1.07 (95% CI 1.01, 1.14)) and SARS-CoV-2 infection. (Table 2) included residing in a LTC facility (OR 16.91), multimorbidity (OR for higher ADG categories compared to the lowest ADG category ranged from 1.35 to 2.05), lower socioeconomic status (OR for the higher income quintiles compared to lowest quintile ranged from 0.60 to 0.86), urban residence (OR 3.52) and younger age (OR 0.89 per 10-year increase in age).

The COVID-19 pandemic remains a major global health crisis, with continued efforts to identify populations most at risk of critical and mortal COVID-19 infection. Our study filled an important gap in knowledge by characterizing the risk of testing and SARS-CoV-2 infection patients with IMIDs.

We have found that despite increased rates of testing among patients with IMIDs, for most IMID groups, the risk of SARS-CoV-2 infection was not elevated, although the risk did vary across IMID diagnoses. Similar to the general population, SARS-CoV-2 infection risk among IMIDs patients was associated with demographic factors including urban living (where the underlying prevalence of the infection is highest), multimorbidity, residing in a LTC facility and lower socioeconomic status [22, 28, 29] .

SARS-CoV-2 infection risk among IMIDs patients has been evaluated in a meta-analysis of 62 observational studies mostly from single centres or regional/national patient registries [12] . The reported cumulative incidence ranged from 0.002% to 0.01% which is substantially lower than our crude estimate of 0.9%, which may be explained by more complete reporting in our study and the fact that our study was performed later in the course of the pandemic allowing accrual of more cases. Importantly, the above study concluded that the odds of contracting SARS-CoV-2 infection is twice as high in patients with IMIDs compared to non-IMID (pooled OR 2.19) which is in contrast to our estimates that showed similar or lower risk of SARS-CoV-2 infection risk for most IMID groups compared to non-IMIDs. The tendency for higher infection risk in previous studies may be related to inherent limitations, such as inaccuracies due to small samples [30] [31] [32] , different definition of SARS-

This article is protected by copyright. All rights reserved CoV-2 infection (e.g. including both laboratory confirmed and clinically suspected cases), highly selected patient populations (e.g. single academic centres, patients on biologic medications) [33, 34] and different reporting methods of COVID-19 in cases and comparators [35] [36] [37] . Additionally, when COVID-19 risk is evaluated in selected populations (e.g. people who tested for SARS-CoV-2, hospitalized patients), the results are susceptible to 'collider bias', a type of selection bias, that can occur when an exposure and an outcome independently influence a 'collider' variable. Since the estimated SARS-CoV-2 infection is influenced by testing which in turn is influenced by IMIDs diagnosis, restricting the analysis to tested patients can lead to artifactual associations[13].

Confounder adjustment is another important issue to consider in any observational study such as ours.

Imbalances in demographic or co-morbid factors between cases and controls that are not accounted for in the analysis could lead to biased comparative risk estimates. To address these potential biases, [11, 39, 40] . Our study results are in line with previous studies that showed increased SARS-CoV-2 testing among patients with chronic diseases [14, 41] . Having any IMID was associated with 20% higher chances of being tested for SARS-CoV-2 compared to non-IMID patients, even after adjusting for other confounding factors including comorbidities, and testing was higher across all IMID groups with OR ranging from 1.11 to 1.42.

Having an IMID or treatment with immunosuppressive medication were some criteria for SARS-CoV-2 testing in the setting of flu-like symptoms in Ontario early in the pandemic[24], which could partly explain differences in testing compared to people without IMIDs; however, rates of testing remained elevated for IMIDs throughout the course of the study after the IMID-specific criteria was removed. Higher rates of testing among those with IMIDs may be explained by several factors including higher awareness and health seeking behaviors, and willingness to get tested due to

This article is protected by copyright. All rights reserved perceived risks of COVID-19 in IMID patients, higher prevalence of disease-related, COVID-19 mimicking symptoms or other infections and pre-existing patient-physician relationships.

The primary strength of our study is the use of a centralized data resource in the setting of a public health system for the entire population. As with any study, there are potential limitations to consider.

First, the IMID case definitions are based on diagnosis codes from physicians and hospital records used for administrative purposes, thus misclassification of IMID diagnoses is possible. It expected that such potential misclassification will shift the results towards the null, therefore, we cannot exclude the possibility that SARS-CoV2 risk in IMID patients is higher than estimated in this study.

To mitigate this risk, whenever possible, we used validated case definitions that showed high performance in prior studies and we used a similar approach requiring multiple IMID diagnosis codes to identify the remaining IMIDs. The population prevalence and demographic characteristics of the different IMIDs provide further face validity to the accuracy of our case definitions. Second, since we do not have access to medication data prior to the age of 65, we could not assess the effect of exposure to corticosteroids and immune modulating agents on SARS-CoV-2 infection risk. In addition, our estimated SARS-CoV-2 infection rates may be underestimated as typically only symptomatic patients and those with known exposures were tested. Due to delays in reporting hospitalizations during the study period, we did not analyze risk of COVID-19 hospitalizations in the present study. Last, access to testing varies in different countries depending on local recommendations, coverage and testing capacity which may affect the generalizability of the results.

While our SARS-CoV-2 testing estimates reflect the situation in Ontario we believe that the general pattern can be extrapolated to other countries as a gradual increased testing capacity resulting in wider testing indications has been a global characteristic of the pandemic [42] . Furthermore, it is likely that our results pertaining to the relative risk of SARS-CoV-2 infection in IMIDs are generalizable as they consider a wide range of patients and carefully matched comparators, adjusted for multiple confounding factors.

In summary, in this large population-based study we found that despite higher rates of SARS-CoV-2 testing among patients with IMIDs, the risk of SARS-CoV-2 infection was not elevated for most IMID groups, yet risk varied across disease subgroups being lower in IBD, MS and psoriasis and higher in RA and iritis. These results provide baseline estimates of the SARS-CoV-2 infection rates in

This article is protected by copyright. All rights reserved IMIDs prior to the rollout of the COVID-19 vaccination campaign and identify factors that predispose to infection. 

This article is protected by copyright. All rights reserved 

Autoimmune diseases co-occurring within individuals and within families: a systematic review

Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity

The prevalence of 30 ICD-10 autoimmune diseases in Denmark

Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia

Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan

High-risk human papilloma virus infection and cervical neoplasm in female inflammatory bowel disease patients: a cross-sectional study

COVID-19 infection and rheumatoid arthritis: Faraway, so close

Infection in systemic lupus erythematosus, similarities, and differences with lupus flare

World Health Organization Transmission of SARS-CoV-2: implications for infection prevention precautions

Sex-and Age-Specific Differences in COVID-19 Testing, Cases, and Outcomes: A Population-Wide Study in Ontario

Understanding Drivers of COVID-19 Racial Disparities: A Population-Level Analysis of COVID-19 Testing among Black and White Populations

Prevalence and clinical outcomes of COVID-19

in patients with autoimmune diseases: a systematic review and meta-analysis

Associations between psychiatric disorders, COVID-19 testing probability and COVID-19 testing results: findings from a population-based study

WHO. Classification of Diseases (ICD) Geneva: World Health Organization (WHO)

Identifying and characterizing psoriasis and psoriatic arthritis patients in Ontario administrative data: a population-based study from 1991 to 2015

Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists

Incidence and prevalence of giant cell arteritis in Ontario

Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada

Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario

COVID-19 Laboratory Testing in Ontario: Patterns of Testing and Characteristics of Individuals Tested, as of

Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study

Accepted Article This article is protected by copyright. All rights reserved 24

Health OMo. COVID-19 Provincial Testing Guidance Update

Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding

The Johns HopkinsACG® System -TechnicalReference GuideVersion

Association Between Nursing Home Crowding and COVID-19 Infection and Mortality in Ontario, Canada

Temporal Associations between Community Incidence of COVID-19 and Nursing Home Outbreaks in Ontario, Canada

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy

Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study

Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts

Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis rheumatol

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

Heterogeneity in testing, diagnosis and outcome in SARS-CoV-2 infection across outbreak settings in the Greater Toronto Area, Canada: an observational study

Disparities in COVID-19 Incidence, Hospitalizations, and Testing, by Area-Level Deprivation -Utah

Understanding the patterns of repeated testing for COVID-19: Association with patient characteristics and outcomes. medRxiv

Testing Pressure on Clinical Laboratories: A Multinational Study Analyzing Google Trends and Over 100 Million Diagnostic Tests

Accepted Article

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved